loading
PHILIPPINE COLLEGE OF HEMATOLOGY AND TRANSFUSION MEDICINE
Upcoming Events:
3rd Midyear Convention : MADAYAW D.A.B.A.W
Upcoming Events: 3rd Midyear Convention : MADAYAW D.A.B.A.W
CLINICAL PROFILE AND OUTCOMES OF ACUTE MYELOID LEUKEMIA (AML) PATIENTS TREATED WITH DECITABINE: A SINGLE CENTER REAL-WORLD EXPERIENCE Nezille Joy R. Lina, MD Contact: 09175669884

ABSTRACT


Rationale and Objectives

Despite the increasing use of decitabine in a subset of acute myeloid leukemia (AML) patients, data on its effectiveness and safety in the real-world setting are scanty. Thus, this study aimed to provide real-world data on the profiles and outcomes of AML patients treated with decitabine.


Methodology

This is a retrospective cohort study of decitabine-treated adult AML patients from January 2015 – December 2022.


Results

The study included 46 adult AML patients. Mean age at decitabine treatment was 58 years old. 89.1% received decitabine alone, and 67.4% received it as first-line. At the beginning of treatment, 58.7% required transfusion of red cells and platelet concentrates, while 71.7% achieved transfusion independence after an average of 3 cycles. The results showed a progression-free survival (PFS) of 12 months, with a positive association between the number of cycles received and the length of PFS. The overall survival (OS) at 1 year is 76.1%. The most common adverse events were hematologic, including thrombocytopenia (63%), anemia (54.4%), and neutropenia (37%).


Importantly, there was no significant difference in achieving transfusion independence, PFS, and OS between patients who received decitabine as first-line, after relapse, or induction failure.


Discussion and Conclusion

The study suggests that decitabine is effective as therapy for first-line and relapse/refractory AML. Patients treated with decitabine in this real-world setting showed higher OS compared to previous real-world studies. Other clinical characteristics and laboratory findings did not significantly differ, further supporting the effectiveness of decitabine in managing AML.